Takeda Pharmaceuticals Inc Archives - Carey Danis & Lowe

First Actos Trial in California Uncovers Takeda’s Deceptive Actos Marketing Tactics

By | Actos, Pharmaceutical litigation, Uncategorized

First Actos Trial in California Uncovers Takeda's Deceptive Actos Marketing TacticsIn 2003, Takeda Pharmaceuticals Inc. expressed concerns about whether Actos users could develop cancer. These reservations on the part of the Japanese pharmaceutical company came to light in court documents filed in a California Superior Court in Los Angeles.

The internal documents reveal that Takeda Pharmaceuticals went so far as to survey doctors about whether a diabetes drug with a label warning about the risk of developing bladder cancer would prevent them from writing a prescription for the drug. After reviewing responses, Takeda Pharmaceuticals concluded that a bladder cancer warning on the Actos label would have a debilitating impact on Actos sales.

Undertaking such a measure is a clear illustration of Takeda Pharmaceuticals’ market-driven philosophy wherein profits far surpass consumer safety in matters of importance.

These internal Takeda documents were filed in the first Actos lawsuit to go to trial. The case is Cooper v. Takeda Pharmaceuticals America, Inc. According to a Bloomberg News report on the Actos trial, there are currently 3,000 Actos lawsuits pending across the country.

These Actos lawsuits including Takeda losing its Actos patent last year are certain to factor in to the company’s reliance on the diabetes drug to be a big moneymaker in 2013. In March 2011, Bloomberg recorded that Actos comprised 27 percent of Takeda’s revenue. Though, this high revenue trend will likely change as Actos has developed a tarnished reputation due to its link to bladder cancer.

In another revealing court filing, Takeda relayed special instructions to its U.S. sales representatives. Essentially, the internal document stated that if safety concerns are not raised, then do not reveal anything about the risk of bladder cancer, and instead, focus on selling the drug.

In response to these documents, a Takeda representative has stated that these documents have been taken out of context.

Lawyers at Carey Danis & Lowe have been paying close attention to the court proceedings in this first Actos lawsuit to go to trial. For those who have been injured by Actos, and especially Actos users who have developed Actos bladder cancer, Carey Danis & Lowe is currently accepting Actos claims, and offering free legal evaluations.

For more information about filing an Actos lawsuit, contact an experienced defective drug lawyer at Carey Danis & Lowe today by calling 800.721.2519 or by submitting a legal claim form

European Medicines Agency’s Takes a Stand on Actos

By | Actos, Pharmaceutical litigation, Uncategorized

Submit Your Claim

[contact-form-7 id=”1660″ title=”mirena”]

European Medicines Agency's Takes a Stand on ActosThe European Medicines Agency made an effort to provide more detail on its conclusion regarding the safety of drugs containing pioglitazone, including the diabetes drug Actos. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded in July 2011 that in patients taking medicines containing pioglitazone, such as Actos, their researchers observed an increased risk in the development of bladder cancer.

Though the European Medicines Agency recognizes the risk for patients to develop bladder cancer, they are still recommending that doctors prescribe drugs such as Actos, and other pioglitazone medications, for the treatment of type 2 diabetes.

Their recommendation does place some patients at an increased risk of developing bladder cancer, and in recognizing the threat of cancer development, the European Medicines Agency has added to their stance on pioglitazone medications that doctors prescribing such drugs must closely monitor their patients for any signs of bladder cancer.

Furthermore, the European Medicines Agency recommended that doctors should use careful discretion in determining when to prescribe drugs such as Actos.

In recognizing the link between Actos and increased risk of bladder cancer, France and Germany have made efforts to halt sales of Actos and other pioglitazone medications.

In the United States, the U.S. Food & Drug Administration is currently analyzing data being collected in a 10 year study conducted by Kaiser Permanente Northern California and Takeda Pharmaceuticals Inc., the manufacturer of Actos. After its review of data from the Kaiser Permanente and Takeda study, the FDA will make a conclusion regarding the safety of Actos and other pioglitazone medications.

Currently, the FDA recommends that Actos not be prescribed to patients who are currently suffering from bladder cancer. Signs of bladder cancer include hematuria, or blood present in urine, painful urination, back and pelvic pain, and a frequent need to urinate. If you are taking Actos and are experiencing any of these bladder cancer symptoms, contact your healthcare provider as soon as possible.

In light of the dangers associated with Actos and other pioglitazone medications, lawyers at Carey Danis & Lowe are currently accepting Actos claims.

If you or someone you love has developed bladder cancer as a result of taking Actos or pioglitazone, understand that you do not have to suffer alone. Our experienced pharmaceutical litigation lawyers work closely with clients to win them much deserved justice and compensation.

Receive a free legal consultation about an Actos lawsuit today by calling a lawyer at Carey Danis & Lowe at 800.721.2519.